Skip to main content
Alkem Laboratories Limited logo

Alkem Laboratories Limited — Investor Relations & Filings

Ticker · ALKEM ISIN · INE540L01014 LEI · 335800GCAE5WIF4PSG69 BSE.NS Manufacturing
Open in API
Filings indexed 1,788 across all filing types
Latest filing 2026-02-17 Investor Presentation
Country IN India
Listing BSE.NS ALKEM

About Alkem Laboratories Limited

https://www.alkemlabs.com/

Alkem Laboratories Limited specializes in the development, manufacturing, and marketing of pharmaceutical and nutraceutical products. The company’s portfolio covers a wide range of therapeutic areas, including anti-infectives, gastrointestinal, pain management, and vitamins, minerals, and nutrients. It has also expanded into chronic therapeutic segments such as cardiology, diabetology, neurology, and dermatology. Alkem operates multiple manufacturing facilities and advanced research and development centers dedicated to formulation development and active pharmaceutical ingredients. The company provides branded generics, generic medications, and active pharmaceutical ingredients to various international markets. Its operations are supported by a robust supply chain and a focus on high-quality production standards to meet global regulatory requirements.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Investor Presentation Classification · 90% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) regarding the schedule of upcoming analyst and institutional investor meetings. It references SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, indicating a regulatory compliance context. The content is about announcing dates and details of investor meetings, not about financial results, reports, or filings. The document length is short (1437 characters), and it does not contain financial data or detailed presentations. This fits the category of an Investor Presentation announcement or update, but since it is specifically about scheduling meetings with analysts and investors, it aligns best with Investor Presentation (IP) filings, which cover detailed presentations for investors focusing on financials, strategy, and market position. Therefore, the classification is Investor Presentation (IP).
2026-02-17 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is a detailed presentation titled 'Investor meet presentation on Alkem MedTech’s strategic way forward' dated February 16, 2026, intended for an investor meeting on February 18, 2026. It includes extensive strategic information about Alkem MedTech's business segments, market opportunities, leadership, product portfolio, and growth plans. The content is clearly a presentation aimed at investors outlining the company's strategy and market positioning rather than a formal financial report, regulatory filing, or announcement of voting results. The document length is substantial (15,000 characters), and it is not a brief announcement or certification. Therefore, it fits the category of an Investor Presentation (IP).
2026-02-16 English
Enclosed please find herewith investor meet presentation on Alkem MedTech''s strategic way forward
Regulatory Filings
2026-02-16 English
Please find attached herewith Q3 FY26- Earnings Call Transcript.
Regulatory Filings
2026-02-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 FY26 earnings conference call for Alkem Laboratories Limited. It includes management presentations, financial performance highlights, strategic discussions about acquisitions, and a Q&A session with analysts. The presence of a full transcript of the earnings call, including management commentary and Q&A, clearly identifies this as a Call Transcript (CT). The document length (15,000 characters) and content confirm it is not a brief announcement or summary but a full transcript. Therefore, the appropriate classification is Call Transcript (CT).
2026-02-16 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges about a USFDA inspection at a subsidiary's manufacturing facility. It mentions the issuance of a Form 483 with observations and the company's response plans. There is no financial data, no report attached or referenced as published, and no mention of annual or quarterly results. The content is an operational regulatory update related to compliance and inspection outcomes. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-02-16 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.